Tarextumab
As of the edition of 20 October 2026, Tarextumab is an antibody: stopped in 2017; acts on NOTCH2 and NOTCH3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2017
- Kind
- Antibody
- Registered trials
- 3, 1 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Tarextumab.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Mereo BioPharma | Lead sponsor of trials | 2010 to now |